Chiara Guarini

发表

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer

C. Porta, G. Pezzicoli, Teresa Grassi, 2021, International journal of molecular sciences.

Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review

C. Porta, F. Mannavola, M. Tucci, 2021, Precision Cancer Medicine.

Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?

F. Giuliani, A. Fancellu, V. Sanna, 2023, Expert opinion on pharmacotherapy.

Immunotherapy in Prostate Cancer: State of Art and New Therapeutic Perspectives

F. Giuliani, P. Fedele, C. Laface, 2023, Current oncology.

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

P. Fedele, C. Laface, Martina Perrone, 2023, Pharmaceutics.

Immunotherapy and Pancreatic Cancer: A Lost Challenge?

R. Memeo, P. Fedele, C. Laface, 2023, Life.

The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions

C. Laface, A. Melaccio, Martina Perrone, 2023, Journal of clinical medicine.

Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?

A. Fancellu, V. Sanna, C. Laface, 2023, Journal of clinical medicine.

Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response

C. Laface, Martina Perrone, Pierluigi De Santis, 2024, Exploration of targeted anti-tumor therapy.

Immunonutrition, Metabolism, and Programmed Cell Death in Lung Cancer: Translating Bench to Bedside

Chiara Guarini, Anna Natalizia Santoro, Palma Fedele, 2024, Biology.